THU0441 Potential Fatality Predictors Caused by Pneumocystis Pneumonia (PCP) in Rheumatic Disease
Identifieur interne : 000A18 ( Istex/Corpus ); précédent : 000A17; suivant : 000A19THU0441 Potential Fatality Predictors Caused by Pneumocystis Pneumonia (PCP) in Rheumatic Disease
Auteurs : R. Yanai ; S. Isojima ; H. Tsukamoto ; T. Tokunaga ; M. Umemura ; H. Furuya ; K. Otsuka ; R. Takahashi ; K. Wakabayashi ; N. Yajima ; Y. Miwa ; T. KasamaSource :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
Abstract
Background Complications of pneumocystis pneumonia (PCP) are one of the predictors of fatality in rheumatic disease. Although clinical characteristics and risk factors for PCP in rheumatic diseases have been studied, there have been no reports of poor prognosis factor of the PCP. Objectives We examined the poor prognosis factors caused by PCP in rheumatic disease at admission. Methods From 2010 to 2012, 28 patients with rheumatic diseases and coexisting PCP were examined retrospectively (rheumatoid arthritis, 19 patients; systemic lupus erythematosus, 2 patients; systemic sclerosis, 2 patients; microscopic polyangiitis, 2 patients; relapsing polychondritis, 1 patient; pseudogout, 1 patient; autoimmune hepatitis, 1 patient). We divided the patients into two groups: surviving patients (group A; n=23) and deceased patients (group B; n=5). Age, sex, smoking history, past history of pulmonary disease, hospitalization and prednisolone dosage were examined. The following were also recorded at admission: white blood cell count, lymphocyte count, arterial blood gas PaO2/FIO2 ratio, serum creatinine level with estimated glomerular filtration rate (eGFR), and the levels of hemoglobin, lactase dehydrogenase(LDH), albumin, C-reactive protein (CRP), β-D-glucan, Krebs von den Lungen-6 (KL-6), pulmonary surfactant-D (SP-D), IgG, and IgA. Results The results were as follows: Conclusions Either higher age, high serum creatinine levels and CRP or low serum albumin levels, IgA and PaO2/FIO2 ratio are potential fatality predictors following admission caused by PCP in patients with rheumatic disease. Disclosure of Interest None Declared
Url:
DOI: 10.1136/annrheumdis-2013-eular.969
Links to Exploration step
ISTEX:73705F50C867C1B225C5C8D6D7B59CF0394D146ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">THU0441 Potential Fatality Predictors Caused by Pneumocystis Pneumonia (PCP) in Rheumatic Disease</title><author><name sortKey="Yanai, R" sort="Yanai, R" uniqKey="Yanai R" first="R." last="Yanai">R. Yanai</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Isojima, S" sort="Isojima, S" uniqKey="Isojima S" first="S." last="Isojima">S. Isojima</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Tsukamoto, H" sort="Tsukamoto, H" uniqKey="Tsukamoto H" first="H." last="Tsukamoto">H. Tsukamoto</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Tokunaga, T" sort="Tokunaga, T" uniqKey="Tokunaga T" first="T." last="Tokunaga">T. Tokunaga</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Umemura, M" sort="Umemura, M" uniqKey="Umemura M" first="M." last="Umemura">M. Umemura</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Furuya, H" sort="Furuya, H" uniqKey="Furuya H" first="H." last="Furuya">H. Furuya</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Otsuka, K" sort="Otsuka, K" uniqKey="Otsuka K" first="K." last="Otsuka">K. Otsuka</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Takahashi, R" sort="Takahashi, R" uniqKey="Takahashi R" first="R." last="Takahashi">R. Takahashi</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Wakabayashi, K" sort="Wakabayashi, K" uniqKey="Wakabayashi K" first="K." last="Wakabayashi">K. Wakabayashi</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yajima, N" sort="Yajima, N" uniqKey="Yajima N" first="N." last="Yajima">N. Yajima</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Miwa, Y" sort="Miwa, Y" uniqKey="Miwa Y" first="Y." last="Miwa">Y. Miwa</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kasama, T" sort="Kasama, T" uniqKey="Kasama T" first="T." last="Kasama">T. Kasama</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:73705F50C867C1B225C5C8D6D7B59CF0394D146E</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/annrheumdis-2013-eular.969</idno><idno type="url">https://api.istex.fr/document/73705F50C867C1B225C5C8D6D7B59CF0394D146E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">THU0441 Potential Fatality Predictors Caused by Pneumocystis Pneumonia (PCP) in Rheumatic Disease</title><author><name sortKey="Yanai, R" sort="Yanai, R" uniqKey="Yanai R" first="R." last="Yanai">R. Yanai</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Isojima, S" sort="Isojima, S" uniqKey="Isojima S" first="S." last="Isojima">S. Isojima</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Tsukamoto, H" sort="Tsukamoto, H" uniqKey="Tsukamoto H" first="H." last="Tsukamoto">H. Tsukamoto</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Tokunaga, T" sort="Tokunaga, T" uniqKey="Tokunaga T" first="T." last="Tokunaga">T. Tokunaga</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Umemura, M" sort="Umemura, M" uniqKey="Umemura M" first="M." last="Umemura">M. Umemura</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Furuya, H" sort="Furuya, H" uniqKey="Furuya H" first="H." last="Furuya">H. Furuya</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Otsuka, K" sort="Otsuka, K" uniqKey="Otsuka K" first="K." last="Otsuka">K. Otsuka</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Takahashi, R" sort="Takahashi, R" uniqKey="Takahashi R" first="R." last="Takahashi">R. Takahashi</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Wakabayashi, K" sort="Wakabayashi, K" uniqKey="Wakabayashi K" first="K." last="Wakabayashi">K. Wakabayashi</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yajima, N" sort="Yajima, N" uniqKey="Yajima N" first="N." last="Yajima">N. Yajima</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Miwa, Y" sort="Miwa, Y" uniqKey="Miwa Y" first="Y." last="Miwa">Y. Miwa</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kasama, T" sort="Kasama, T" uniqKey="Kasama T" first="T." last="Kasama">T. Kasama</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-06">2013-06</date><biblScope unit="volume">72</biblScope><biblScope unit="issue">Suppl 3</biblScope><biblScope unit="page" from="A313">A313</biblScope></imprint><idno type="ISSN">0003-4967</idno></series><idno type="istex">73705F50C867C1B225C5C8D6D7B59CF0394D146E</idno><idno type="DOI">10.1136/annrheumdis-2013-eular.969</idno><idno type="href">annrheumdis-72-A313-3.pdf</idno><idno type="ArticleID">annrheumdis-2013-eular.969</idno><idno type="local">annrheumdis;72/Suppl_3/A313-c</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background Complications of pneumocystis pneumonia (PCP) are one of the predictors of fatality in rheumatic disease. Although clinical characteristics and risk factors for PCP in rheumatic diseases have been studied, there have been no reports of poor prognosis factor of the PCP. Objectives We examined the poor prognosis factors caused by PCP in rheumatic disease at admission. Methods From 2010 to 2012, 28 patients with rheumatic diseases and coexisting PCP were examined retrospectively (rheumatoid arthritis, 19 patients; systemic lupus erythematosus, 2 patients; systemic sclerosis, 2 patients; microscopic polyangiitis, 2 patients; relapsing polychondritis, 1 patient; pseudogout, 1 patient; autoimmune hepatitis, 1 patient). We divided the patients into two groups: surviving patients (group A; n=23) and deceased patients (group B; n=5). Age, sex, smoking history, past history of pulmonary disease, hospitalization and prednisolone dosage were examined. The following were also recorded at admission: white blood cell count, lymphocyte count, arterial blood gas PaO2/FIO2 ratio, serum creatinine level with estimated glomerular filtration rate (eGFR), and the levels of hemoglobin, lactase dehydrogenase(LDH), albumin, C-reactive protein (CRP), β-D-glucan, Krebs von den Lungen-6 (KL-6), pulmonary surfactant-D (SP-D), IgG, and IgA. Results The results were as follows: Conclusions Either higher age, high serum creatinine levels and CRP or low serum albumin levels, IgA and PaO2/FIO2 ratio are potential fatality predictors following admission caused by PCP in patients with rheumatic disease. Disclosure of Interest None Declared</div></front></TEI><istex><corpusName>bmj</corpusName><author><json:item><name>R. Yanai</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>S. Isojima</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>H. Tsukamoto</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>T. Tokunaga</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>M. Umemura</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>H. Furuya</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>K. Otsuka</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>R. Takahashi</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>K. Wakabayashi</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>N. Yajima</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>Y. Miwa</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>T. Kasama</name><affiliations><json:string>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</json:string></affiliations></json:item></author><articleId><json:string>annrheumdis-2013-eular.969</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>abstract</json:string></originalGenre><abstract>Background Complications of pneumocystis pneumonia (PCP) are one of the predictors of fatality in rheumatic disease. Although clinical characteristics and risk factors for PCP in rheumatic diseases have been studied, there have been no reports of poor prognosis factor of the PCP. Objectives We examined the poor prognosis factors caused by PCP in rheumatic disease at admission. Methods From 2010 to 2012, 28 patients with rheumatic diseases and coexisting PCP were examined retrospectively (rheumatoid arthritis, 19 patients; systemic lupus erythematosus, 2 patients; systemic sclerosis, 2 patients; microscopic polyangiitis, 2 patients; relapsing polychondritis, 1 patient; pseudogout, 1 patient; autoimmune hepatitis, 1 patient). We divided the patients into two groups: surviving patients (group A; n=23) and deceased patients (group B; n=5). Age, sex, smoking history, past history of pulmonary disease, hospitalization and prednisolone dosage were examined. The following were also recorded at admission: white blood cell count, lymphocyte count, arterial blood gas PaO2/FIO2 ratio, serum creatinine level with estimated glomerular filtration rate (eGFR), and the levels of hemoglobin, lactase dehydrogenase(LDH), albumin, C-reactive protein (CRP), β-D-glucan, Krebs von den Lungen-6 (KL-6), pulmonary surfactant-D (SP-D), IgG, and IgA. Results The results were as follows: Conclusions Either higher age, high serum creatinine levels and CRP or low serum albumin levels, IgA and PaO2/FIO2 ratio are potential fatality predictors following admission caused by PCP in patients with rheumatic disease. Disclosure of Interest None Declared</abstract><qualityIndicators><score>6.163</score><pdfVersion>1.4</pdfVersion><pdfPageSize>594.72 x 841.68 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1642</abstractCharCount><pdfWordCount>2927</pdfWordCount><pdfCharCount>17402</pdfCharCount><pdfPageCount>2</pdfPageCount><abstractWordCount>228</abstractWordCount></qualityIndicators><title>THU0441 Potential Fatality Predictors Caused by Pneumocystis Pneumonia (PCP) in Rheumatic Disease</title><genre><json:string>abstract</json:string></genre><host><volume>72</volume><publisherId><json:string>ard</json:string></publisherId><pages><first>A313</first></pages><issn><json:string>0003-4967</json:string></issn><issue>Suppl 3</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-2060</json:string></eissn><title>Annals of the Rheumatic Diseases</title></host><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1136/annrheumdis-2013-eular.969</json:string></doi><id>73705F50C867C1B225C5C8D6D7B59CF0394D146E</id><score>0.2409108</score><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/73705F50C867C1B225C5C8D6D7B59CF0394D146E/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/73705F50C867C1B225C5C8D6D7B59CF0394D146E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/73705F50C867C1B225C5C8D6D7B59CF0394D146E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">THU0441 Potential Fatality Predictors Caused by Pneumocystis Pneumonia (PCP) in Rheumatic Disease</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><availability><p>© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</p></availability><date>2013</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">THU0441 Potential Fatality Predictors Caused by Pneumocystis Pneumonia (PCP) in Rheumatic Disease</title><author xml:id="author-1"><persName><forename type="first">R.</forename><surname>Yanai</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author><author xml:id="author-2"><persName><forename type="first">S.</forename><surname>Isojima</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author><author xml:id="author-3"><persName><forename type="first">H.</forename><surname>Tsukamoto</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author><author xml:id="author-4"><persName><forename type="first">T.</forename><surname>Tokunaga</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author><author xml:id="author-5"><persName><forename type="first">M.</forename><surname>Umemura</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author><author xml:id="author-6"><persName><forename type="first">H.</forename><surname>Furuya</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author><author xml:id="author-7"><persName><forename type="first">K.</forename><surname>Otsuka</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author><author xml:id="author-8"><persName><forename type="first">R.</forename><surname>Takahashi</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author><author xml:id="author-9"><persName><forename type="first">K.</forename><surname>Wakabayashi</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author><author xml:id="author-10"><persName><forename type="first">N.</forename><surname>Yajima</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author><author xml:id="author-11"><persName><forename type="first">Y.</forename><surname>Miwa</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author><author xml:id="author-12"><persName><forename type="first">T.</forename><surname>Kasama</surname></persName><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation></author></analytic><monogr><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="pISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-06"></date><biblScope unit="volume">72</biblScope><biblScope unit="issue">Suppl 3</biblScope><biblScope unit="page" from="A313">A313</biblScope></imprint></monogr><idno type="istex">73705F50C867C1B225C5C8D6D7B59CF0394D146E</idno><idno type="DOI">10.1136/annrheumdis-2013-eular.969</idno><idno type="href">annrheumdis-72-A313-3.pdf</idno><idno type="ArticleID">annrheumdis-2013-eular.969</idno><idno type="local">annrheumdis;72/Suppl_3/A313-c</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2013</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Background Complications of pneumocystis pneumonia (PCP) are one of the predictors of fatality in rheumatic disease. Although clinical characteristics and risk factors for PCP in rheumatic diseases have been studied, there have been no reports of poor prognosis factor of the PCP. Objectives We examined the poor prognosis factors caused by PCP in rheumatic disease at admission. Methods From 2010 to 2012, 28 patients with rheumatic diseases and coexisting PCP were examined retrospectively (rheumatoid arthritis, 19 patients; systemic lupus erythematosus, 2 patients; systemic sclerosis, 2 patients; microscopic polyangiitis, 2 patients; relapsing polychondritis, 1 patient; pseudogout, 1 patient; autoimmune hepatitis, 1 patient). We divided the patients into two groups: surviving patients (group A; n=23) and deceased patients (group B; n=5). Age, sex, smoking history, past history of pulmonary disease, hospitalization and prednisolone dosage were examined. The following were also recorded at admission: white blood cell count, lymphocyte count, arterial blood gas PaO2/FIO2 ratio, serum creatinine level with estimated glomerular filtration rate (eGFR), and the levels of hemoglobin, lactase dehydrogenase(LDH), albumin, C-reactive protein (CRP), β-D-glucan, Krebs von den Lungen-6 (KL-6), pulmonary surfactant-D (SP-D), IgG, and IgA. Results The results were as follows: Conclusions Either higher age, high serum creatinine levels and CRP or low serum albumin levels, IgA and PaO2/FIO2 ratio are potential fatality predictors following admission caused by PCP in patients with rheumatic disease. Disclosure of Interest None Declared</p></abstract></profileDesc><revisionDesc><change when="2013-06">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-10-4">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/73705F50C867C1B225C5C8D6D7B59CF0394D146E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="abstract" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="hwp">annrheumdis</journal-id><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-id journal-id-type="publisher-id">ard</journal-id><journal-title>Annals of the Rheumatic Diseases</journal-title><abbrev-journal-title abbrev-type="publisher">Ann Rheum Dis</abbrev-journal-title><abbrev-journal-title>Ann Rheum Dis</abbrev-journal-title><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">annrheumdis-2013-eular.969</article-id><article-id pub-id-type="doi">10.1136/annrheumdis-2013-eular.969</article-id><article-id pub-id-type="other">annrheumdis;72/Suppl_3/A313-c</article-id><article-id pub-id-type="other">annrheumdis;annrheumdis-2013-eular.969</article-id><article-id pub-id-type="other">A313.3</article-id><article-id pub-id-type="other">annrheumdis-2013-eular.969</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject><subj-group subj-group-type="heading"><subject>Infection-related rheumatic diseases</subject></subj-group></subj-group></article-categories><title-group><article-title>THU0441 Potential Fatality Predictors Caused by Pneumocystis Pneumonia (PCP) in Rheumatic Disease</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yanai</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Isojima</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tsukamoto</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tokunaga</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Umemura</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Furuya</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Otsuka</surname><given-names>K.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Takahashi</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wakabayashi</surname><given-names>K.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yajima</surname><given-names>N.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Miwa</surname><given-names>Y.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kasama</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="AF04411"><sup>1</sup></xref></contrib></contrib-group><aff id="AF04411"><sup>1</sup>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</aff><pub-date pub-type="ppub"><month>06</month><year>2013</year></pub-date><volume>72</volume><volume-id pub-id-type="other">72</volume-id><volume-id pub-id-type="other">72</volume-id><issue>Suppl 3</issue><issue-id pub-id-type="other">annrheumdis;72/Suppl_3</issue-id><issue-id pub-id-type="other" content-type="supplement">Suppl_3</issue-id><issue-id pub-id-type="other">72/Suppl_3</issue-id><issue-title>Annual European Congress of Rheumatology EULAR abstracts 2013, 12–15 June 2013, Spain</issue-title><fpage seq="3">A313</fpage><permissions><copyright-statement>© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2013</copyright-year></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="annrheumdis-72-A313-3.pdf"></self-uri><abstract><sec><title>Background</title><p>Complications of pneumocystis pneumonia (PCP) are one of the predictors of fatality in rheumatic disease. Although clinical characteristics and risk factors for PCP in rheumatic diseases have been studied, there have been no reports of poor prognosis factor of the PCP.</p></sec><sec><title>Objectives</title><p>We examined the poor prognosis factors caused by PCP in rheumatic disease at admission.</p></sec><sec><title>Methods</title><p>From 2010 to 2012, 28 patients with rheumatic diseases and coexisting PCP were examined retrospectively (rheumatoid arthritis, 19 patients; systemic lupus erythematosus, 2 patients; systemic sclerosis, 2 patients; microscopic polyangiitis, 2 patients; relapsing polychondritis, 1 patient; pseudogout, 1 patient; autoimmune hepatitis, 1 patient). We divided the patients into two groups: surviving patients (group A; n=23) and deceased patients (group B; n=5). Age, sex, smoking history, past history of pulmonary disease, hospitalization and prednisolone dosage were examined. The following were also recorded at admission: white blood cell count, lymphocyte count, arterial blood gas PaO<sub>2</sub>/F<sub>I</sub>O<sub>2</sub> ratio, serum creatinine level with estimated glomerular filtration rate (eGFR), and the levels of hemoglobin, lactase dehydrogenase(LDH), albumin, C-reactive protein (CRP), β-D-glucan, Krebs von den Lungen-6 (KL-6), pulmonary surfactant-D (SP-D), IgG, and IgA.</p></sec><sec><title>Results</title><p>The results were as follows:</p><fig id="F1" position="float"><graphic xlink:href="annrheumdis-72-A313-3-F1.jpg" alt-version="no" position="float" xlink:type="simple"></graphic></fig></sec><sec><title>Conclusions</title><p>Either higher age, high serum creatinine levels and CRP or low serum albumin levels, IgA and PaO<sub>2</sub>/F<sub>I</sub>O<sub>2</sub> ratio are potential fatality predictors following admission caused by PCP in patients with rheumatic disease.</p></sec><sec><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>THU0441 Potential Fatality Predictors Caused by Pneumocystis Pneumonia (PCP) in Rheumatic Disease</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>THU0441 Potential Fatality Predictors Caused by Pneumocystis Pneumonia (PCP) in Rheumatic Disease</title></titleInfo><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Yanai</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Isojima</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Tsukamoto</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Tokunaga</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Umemura</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Furuya</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Otsuka</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Takahashi</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Wakabayashi</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Yajima</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Miwa</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Kasama</namePart><affiliation>Division of Rheumatology, Department of Medicine, Showa University, School Of Medicine, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="abstract" displayLabel="abstract"></genre><originInfo><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><dateIssued encoding="w3cdtf">2013-06</dateIssued><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Background Complications of pneumocystis pneumonia (PCP) are one of the predictors of fatality in rheumatic disease. Although clinical characteristics and risk factors for PCP in rheumatic diseases have been studied, there have been no reports of poor prognosis factor of the PCP. Objectives We examined the poor prognosis factors caused by PCP in rheumatic disease at admission. Methods From 2010 to 2012, 28 patients with rheumatic diseases and coexisting PCP were examined retrospectively (rheumatoid arthritis, 19 patients; systemic lupus erythematosus, 2 patients; systemic sclerosis, 2 patients; microscopic polyangiitis, 2 patients; relapsing polychondritis, 1 patient; pseudogout, 1 patient; autoimmune hepatitis, 1 patient). We divided the patients into two groups: surviving patients (group A; n=23) and deceased patients (group B; n=5). Age, sex, smoking history, past history of pulmonary disease, hospitalization and prednisolone dosage were examined. The following were also recorded at admission: white blood cell count, lymphocyte count, arterial blood gas PaO2/FIO2 ratio, serum creatinine level with estimated glomerular filtration rate (eGFR), and the levels of hemoglobin, lactase dehydrogenase(LDH), albumin, C-reactive protein (CRP), β-D-glucan, Krebs von den Lungen-6 (KL-6), pulmonary surfactant-D (SP-D), IgG, and IgA. Results The results were as follows: Conclusions Either higher age, high serum creatinine levels and CRP or low serum albumin levels, IgA and PaO2/FIO2 ratio are potential fatality predictors following admission caused by PCP in patients with rheumatic disease. Disclosure of Interest None Declared</abstract><relatedItem type="host"><titleInfo><title>Annals of the Rheumatic Diseases</title></titleInfo><titleInfo type="abbreviated"><title>Ann Rheum Dis</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0003-4967</identifier><identifier type="eISSN">1468-2060</identifier><identifier type="PublisherID">ard</identifier><identifier type="PublisherID-hwp">annrheumdis</identifier><identifier type="PublisherID-nlm-ta">Ann Rheum Dis</identifier><part><date>2013</date><detail type="title"><title>Annual European Congress of Rheumatology EULAR abstracts 2013, 12–15 June 2013, Spain</title></detail><detail type="volume"><caption>vol.</caption><number>72</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 3</number></detail><extent unit="pages"><start>A313</start></extent></part></relatedItem><identifier type="istex">73705F50C867C1B225C5C8D6D7B59CF0394D146E</identifier><identifier type="DOI">10.1136/annrheumdis-2013-eular.969</identifier><identifier type="href">annrheumdis-72-A313-3.pdf</identifier><identifier type="ArticleID">annrheumdis-2013-eular.969</identifier><identifier type="local">annrheumdis;72/Suppl_3/A313-c</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</accessCondition><recordInfo><recordContentSource>BMJ</recordContentSource></recordInfo></mods></metadata><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/73705F50C867C1B225C5C8D6D7B59CF0394D146E/annexes/jpeg</uri></json:item></annexes><enrichments><json:item><type>multicat</type><uri>https://api.istex.fr/document/73705F50C867C1B225C5C8D6D7B59CF0394D146E/enrichments/multicat</uri></json:item><json:item><type>refBibs</type><uri>https://api.istex.fr/document/73705F50C867C1B225C5C8D6D7B59CF0394D146E/enrichments/refBibs</uri></json:item></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:73705F50C867C1B225C5C8D6D7B59CF0394D146E
|texte= THU0441 Potential Fatality Predictors Caused by Pneumocystis Pneumonia (PCP) in Rheumatic Disease
}}
| This area was generated with Dilib version V0.6.25. |  |